bepridil has been researched along with Adenocarcinoma, Basal Cell in 1 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Linn, SC | 1 |
| Giaccone, G | 1 |
| Pinedo, HM | 1 |
1 other study available for bepridil and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Bepridil; Clinical Trials as Topic; Colorectal Neoplas | 1994 |